Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain (IMIOXC)
Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain: Predictors of Response - a Randomised, Double-blind, Placebo-controlled Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Aarhus, Denmark, 8000
- Danish Pain Research Center, Aarhus University Hospital
-
Odense, Denmark, DK-5000
- Department of Neurology, Odense University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age > 18 years old
- definite or probable neuropathic pain
- diagnosis of polyneuropathy, postherpetic neuralgia or peripheral nerve inju
- pain duration > 3 months
- pain rating at baseline >= 4 point NRS
- Informed consent
Exclusion Criteria:
- other non-neuropathic pain condition
- allergy to oxcarbazepine
- renal or hepatic impairment
- epilepsy
- depression and other serious psychiatric disorders
- serious medical condition
- previous treatment for neuropathic that cannot be stopped
- pregnancy
- patients expected not to be able to comply with study protocol
- treatment with anticonvulsants, antidepressant or opioids
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: placebo
|
Oxcarbazepine capsules 300 mg is gradually increased from 300 mg/day to 2400 mg/day Placebo capsules increase from 1/day to 8/day
Other Names:
|
|
Experimental: oxcarbazepine
Oxcarbazepine is gradually increased during 21 days from 300 mg x 1 daily to 2400 mg, and kept on that dose ( 2400 mg) for three weeks.
|
Oxcarbazepine capsules 300 mg is gradually increased from 300 mg/day to 2400 mg/day Placebo capsules increase from 1/day to 8/day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total pain rated on numeric rating scale
Time Frame: Measurements from week 6 of treatment period
|
Pain is rated daily on 0-10 point numeric rating scales.
From the daily ratings from week 6 of each treatment period a median value is determined and used for data analysis.
The analysis will compare scores between treatments (oxcabazepine vs placebo) and treatment effects (placebo-oxcarbazepine) between groups irritable nociceptor vs non-irritable nociceptors and some other subgroups.
|
Measurements from week 6 of treatment period
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Response defined as at least 50% reduction in pain score
Time Frame: Week 6 of each treatment period vs. baseline
|
Response defined as 50% reduction in pain score (median value week 6 of treatment period compared to median value during baseline period).
Repsonse rates for each treatment and each phenotype will be calculated
|
Week 6 of each treatment period vs. baseline
|
|
Neuropathic Pain Symptom Inventory
Time Frame: Week 6 of each treatment period
|
Different pain dimensions as rated by Neuropathic Pain Symptom Inventory
|
Week 6 of each treatment period
|
|
Patient Global Impression of Change
Time Frame: Week 6 of each treatment period
|
Week 6 of each treatment period
|
|
|
Rating of evoked pain
Time Frame: Week 6 of each treatment period
|
Rating on numeric rating scales of pain induced by stimulation with cold rollers, stiff von Frey hain and dynamic touch with rubber sponge
|
Week 6 of each treatment period
|
|
Sleep disturbance
Time Frame: Week 6 of each treatment period
|
Numeric rating scale ratings of pain induced sleep disturbance, median value of ratings from week 6 of each treatment period
|
Week 6 of each treatment period
|
|
Quality of life
Time Frame: Week 6 of each treatment period
|
Rating of quality of life with numeric rating scale
|
Week 6 of each treatment period
|
|
Use of escape medication
Time Frame: Week 6 of each treatment period
|
Number of paracetamol 500 mg used during the last week of each treamtent period
|
Week 6 of each treatment period
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Søren H Sindrup, MD, Department of Neurology, Odense University Hospital
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Pain
- Neurologic Manifestations
- Wounds and Injuries
- Neuromuscular Diseases
- Peripheral Nervous System Diseases
- Trauma, Nervous System
- Neuralgia
- Polyneuropathies
- Neuralgia, Postherpetic
- Peripheral Nerve Injuries
- Molecular Mechanisms of Pharmacological Action
- Membrane Transport Modulators
- Anticonvulsants
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- Oxcarbazepine
Other Study ID Numbers
Other Study ID Numbers
- IMIOXC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.